Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018

Cecilia G Carvalhaes; Dee Shortridge; Helio S Sader; Mariana Castanheira

doi:10.1128/AAC.02177-19

Back

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018

Journal article

Open access

Peer reviewed

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018

Cecilia G Carvalhaes, Dee Shortridge, Helio S Sader and Mariana Castanheira

Antimicrobial agents and chemotherapy, Vol.64(3), e02177-19

02/21/2020

DOI: 10.1128/AAC.02177-19

PMCID: PMC7038313

PMID: 31907187

Files and links (1)

url

https://doi.org/10.1128/AAC.02177-19View

Published (Version of record) Open Access

Abstract

Meropenem-vaborbactam is approved to treat hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), in Europe. Meropenem-vaborbactam activity was evaluated against 3,193 and 4,790 isolates causing pneumonia, including VAP, in hospitalized patients in the United States. Susceptibility testing was performed by using the broth microdilution method, and all carbapenem-resistant isolates were submitted for whole-genome sequencing. Meropenem-vaborbactam exhibited almost complete activity against (>99.9% susceptible), including carbapenem-resistant (CRE), and was also very active against isolates (89.5% susceptible).

Anti-Bacterial Agents - pharmacology

Boronic Acids - pharmacology

Enterobacteriaceae - drug effects

Enterobacteriaceae - genetics

Enterobacteriaceae - pathogenicity

Hospitals

Humans

Meropenem - pharmacology

Microbial Sensitivity Tests

Pneumonia - microbiology

Whole Genome Sequencing

Details

Title: Subtitle: Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018
Creators: Cecilia G Carvalhaes - JMI Laboratories
Dee Shortridge - JMI Laboratories
Helio S Sader - JMI Laboratories
Mariana Castanheira - JMI Laboratories
Resource Type: Journal article
Publication Details: Antimicrobial agents and chemotherapy, Vol.64(3), e02177-19
DOI: 10.1128/AAC.02177-19
PMID: 31907187
PMCID: PMC7038313
NLM abbreviation: Antimicrob Agents Chemother
ISSN: 0066-4804
eISSN: 1098-6596
Grant note: name: Melinta Therapeutics, Inc
Language: English
Date published: 02/21/2020
Academic Unit: Pathology
Record Identifier: 9984184007102771

Metrics

22 Record Views

29 Times Cited - Web of Science